A director at Danske Bank AS sold 10,000 shares at 274.400DKK and the significance rating of the trade was 78/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
Danske Bank A/S, ledende medarbejderes transaktioner 22. oktober 2025 Indberetning nr. 71/2025 Ændring i aktiebesiddelser hos Danske Banks indberetningspligtige i henhold til EU-forordningen om markedsmisbrug I forbindelse med Danske Bank A/S’ aktietilbagekøbsprogram sælger APMH Invest A/S løbende aktier i Danske Bank A/S pro rata. For yderligere detaljer henvises til de vedhæftede skemaer, hvori transaktioner udført af personer med ledelsesansvar og personer med nær tilknytning til disse skal indberettes og offentliggøres. Kontakt: Stefan Kailay Wind, Head of Corporate Communications ...
Danske Bank A/S, transactions by persons discharging managerial responsibilities 22 October 2025 Notification no. 71/2025 Transactions made by persons obliged to report transactions to the Danish FSA and Nasdaq Copenhagen, cf. the EU Market Abuse Regulation. In connection with the share buy-back program in Danske Bank A/S, APMH Invest A/S continuously sells shares pro rata. For further details, please find the attached templates for notifications and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them. Contact: S...
Genmab Commences Tender Offer for All Issued and Outstanding Common Shares of Merus N.V. Media ReleaseCOPENHAGEN, Denmark; October 21, 2025 (Nasdaq: GMAB) (“Genmab”) announced today that it is commencing, through a wholly owned subsidiary, Genmab Holding II B.V. (“Purchaser”), a cash tender offer (the “Offer”) to purchase all of the issued and outstanding common shares (“Common Shares”) of (Nasdaq: MRUS) (“Merus”) for $97.00 per Common Share in cash (the “Offer Consideration”), less any applicable withholding taxes and without interest. The Offer is being made pursuant to the previously...
Aktietilbagekøb i Danske Bank: Transaktioner i uge 42 Selskabsmeddelelse nr. 47 2025Danske BankBernstorffsgade 40DK-1577 København VTel. 020. oktober 2025Page 1 of 1Aktietilbagekøb i Danske Bank: Transaktioner i uge 42Den 7. februar 2025, offentliggjorde Danske Bank A/S et aktietilbagekøbsprogram for samlet 5 mia. kr. med maksimalt 45.000.000 aktier i perioden fra 10. februar 2025 til senest 30. januar 2026 - som beskrevet i selskabsmeddelelse nr. 6 2025. Aktietilbagekøbsprogrammet gennemføres i henhold til artikel 5 i Europa-Parlamentets og Rådets forordning (EU) nr. 596/2014 af 16. ap...
Danske Bank share buy-back programme: transactions in week 42 Company announcement no. 47 2025Danske BankBernstorffsgade 40DK-1577 København VTel. 020 October 2025Page 1 of 1Danske Bank share buy-back programme: transactions in week 42On 7 February 2025, Danske Bank A/S announced a share buy-back programme for a total of DKK 5 billion, with a maximum of 45,000,000 shares, in the period from 10 February 2025 to 30 January 2026, at the latest, as described in company announcement no. 6 2025. The Programme is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 of the Eu...
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer Media Release COPENHAGEN, Denmark; October 18, 2025 Updated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S®) 100 mg/m2 demonstrated 50% confirmed objective response rate (ORR), including two complete responses (CR), regardless of FRα expressionA Phase 3 trial in endometrial cancer is underwayU.S. FDA recently granted Breakthrough Therapy Designation to Rina-S for advanced endometria...
Danske Bank A/S, ledende medarbejderes transaktioner 15. oktober 2025 Indberetning nr. 70/2025 Ændring i aktiebesiddelser hos Danske Banks indberetningspligtige i henhold til EU-forordningen om markedsmisbrug I forbindelse med Danske Bank A/S’ aktietilbagekøbsprogram sælger APMH Invest A/S løbende aktier i Danske Bank A/S pro rata. For yderligere detaljer henvises til de vedhæftede skemaer, hvori transaktioner udført af personer med ledelsesansvar og personer med nær tilknytning til disse skal indberettes og offentliggøres. Kontakt: Stefan Kailay Wind, Head of Corporate Communications ...
Danske Bank A/S, transactions by persons discharging managerial responsibilities 15 October 2025 Notification no. 70/2025 Transactions made by persons obliged to report transactions to the Danish FSA and Nasdaq Copenhagen, cf. the EU Market Abuse Regulation. In connection with the share buy-back program in Danske Bank A/S, APMH Invest A/S continuously sells shares pro rata. For further details, please find the attached templates for notifications and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them. Contact: S...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2025 Company Announcement Net sales of DARZALEX® in the third quarter of 2025 totaled USD 3,672 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; October 14, 2025 – (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by J&J were USD 3,...
Subsea 7 S.A. - 3Q25 earnings call notification Luxembourg – 13 October 2025 – Subsea 7 S.A. (Oslo Børs: SUBC, ADR: SUBCY) will publish its third quarter 2025 results for the period ended 30 September 2025 on Thursday 20 November 2025 at 08:00 CET. A conference call and simultaneous webcast for the investment community will be held on Thursday 20 November 2025 at 12:00 UK / 13:00 CET. From 08:00 CET the results announcement and the presentation to be reviewed during the conference call and webcast will be available on the Subsea7 website: Conference call registration: Phone: -c...
Aktietilbagekøb i Danske Bank: Transaktioner i uge 41 Selskabsmeddelelse nr. 46 2025Danske BankBernstorffsgade 40DK-1577 København VTel. 013. oktober 2025Page 1 of 1Aktietilbagekøb i Danske Bank: Transaktioner i uge 41Den 7. februar 2025, offentliggjorde Danske Bank A/S et aktietilbagekøbsprogram for samlet 5 mia. kr. med maksimalt 45.000.000 aktier i perioden fra 10. februar 2025 til senest 30. januar 2026 - som beskrevet i selskabsmeddelelse nr. 6 2025. Aktietilbagekøbsprogrammet gennemføres i henhold til artikel 5 i Europa-Parlamentets og Rådets forordning (EU) nr. 596/2014 af 16. ap...
Danske Bank share buy-back programme: transactions in week 41 Company announcement no. 46 2025Danske BankBernstorffsgade 40DK-1577 København VTel. 013 October 2025Page 1 of 1Danske Bank share buy-back programme: transactions in week 41On 7 February 2025, Danske Bank A/S announced a share buy-back programme for a total of DKK 5 billion, with a maximum of 45,000,000 shares, in the period from 10 February 2025 to 30 January 2026, at the latest, as described in company announcement no. 6 2025. The Programme is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 of the Eu...
Danske Bank A/S, ledende medarbejderes transaktioner 9. oktober 2025 Indberetning nr. 69/2025 Ændring i aktiebesiddelser hos Danske Banks indberetningspligtige i henhold til EU-forordningen om markedsmisbrug I forbindelse med Danske Bank A/S’ aktietilbagekøbsprogram sælger APMH Invest A/S løbende aktier i Danske Bank A/S pro rata. For yderligere detaljer henvises til de vedhæftede skemaer, hvori transaktioner udført af personer med ledelsesansvar og personer med nær tilknytning til disse skal indberettes og offentliggøres. Kontakt: Stefan Kailay Wind, Head of Corporate Communications &...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.